CTV Frequency Management for Pharma Campaigns
Manage pharma CTV frequency across households, apps, publishers, DSPs, and direct buys with identity-aware reporting and marginal reach rules.
The short answer
Set CTV frequency at the household or person unit the identity system can actually support, then manage duplication across publishers, DSPs, and direct buys. A cap inside one platform is not a portfolio cap.
Diagnose the unit first
Document whether reach and frequency are device, account, household, or modeled-person based. Shared televisions make person-level exposure uncertain. Report that limitation instead of translating households into people without evidence.
Build a frequency distribution
A campaign average can hide a long tail. Report households reached 1, 2, 3 to 5, 6 to 10, and 11-plus times, along with impressions and spend in each band. Segment by supply source, audience, creative, and week.
| Signal | Likely interpretation | Action to test |
|---|---|---|
| Rising average, flat unique reach | Saturation | Tighten cap or add supply |
| High single-source frequency | Concentrated inventory | Cap source or rebalance |
| High cross-source duplication | Fragmented buying | Consolidate identity/control |
| Low frequency and weak reach | Underfunded or scarce supply | Concentrate plan or extend time |
Tie caps to message and decision
There is no universal pharma CTV cap. Creative length, campaign duration, audience size, message complexity, other video exposure, and outcome latency all matter. Use reach curves, brand or outcome evidence, and complaint or quality signals. Do not infer a clinical effect from media frequency.
Coordinate creative sequencing
If multiple approved messages have distinct jobs, define sequence and fallback behavior. Fair-balance and promotional requirements still apply to each relevant execution; frequency strategy cannot compensate for incomplete risk presentation (FDA).
Hypothetical example
A platform reports average frequency of 4, but joined publisher logs suggest the top 10% of households received 18 or more exposures across buys. The portfolio needs deduplication and source-level caps. Numbers are illustrative.
Common frequency mistakes in pharma CTV
Trusting each platform's cap as the total. A household capped at three per week in one DSP can still see three more from a publisher direct buy and three from another platform. Only a joined view shows the real exposure.
Treating a household as a person. Frequency of six to a household of four people is not six exposures to the target patient. Report the unit honestly.
Setting caps once. Reach curves change as a flight matures and as supply shifts. Review the distribution at least every two weeks and after any partner or budget change.
Ignoring creative rotation. When several approved spots are in rotation, the same household may see different messages in an order nobody planned. Decide whether order matters and, if it does, configure sequencing where the platform supports it.
Cutting frequency without checking reach. Tighter caps sometimes push delivery into lower-quality supply as platforms search for new households. Watch quality metrics after every cap change. The deduplicated reach guide covers how to read cross-channel overlap alongside frequency.
Practical takeaway
Manage the distribution, not the average. The next step is a weekly household-frequency table that joins all available buying routes and identifies the spend trapped in high-frequency bands.
Sources
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.